Core Viewpoint - The controversy surrounding the collagen content in the "Kefumei" product from Giant Biological has raised significant questions about product labeling and industry standards, highlighting potential discrepancies between claimed and actual ingredient levels [4][6][9]. Group 1: Allegations and Findings - Dr. Hao Yu's report claims that the actual collagen content in the "Kefumei" collagen stick is only 0.0177%, significantly below the regulatory threshold of 0.1% [1][3]. - The report also indicates that key component glycine was not detected in the product, challenging the validity of Giant Biological's claims regarding their recombinant collagen technology [3][5]. - The detection method used by Dr. Hao Yu, which includes high-precision HPLC and calibration with 18 amino acid internal standards, is said to be highly sensitive and reliable [5]. Group 2: Company Response - In response to the allegations, Giant Biological emphasized the compliance of their products with regulatory standards and stated that their internal testing showed collagen content above 0.1% [6][8]. - The company criticized the detection methods used by Dr. Hao Yu as not being recognized by industry standards and claimed that the results lacked credibility due to methodological issues [6][7]. - Giant Biological announced that they have engaged multiple third-party testing agencies to verify their product's content and will disclose results once available [6][8]. Group 3: Industry Context - The incident has highlighted a broader issue within the recombinant collagen industry, where there is currently no unified testing method or standard, leading to significant discrepancies in reported results [9]. - The ongoing debate reflects a conflict between technical standards and commercial interests, impacting consumer trust and transparency in the medical aesthetics sector [9].
“可复美”一年卖出45亿元，重组胶原蛋白巨头巨子生物发长文释疑